Erik de Clercq
Directeur/Bestuurslid bij FermaVir Pharmaceuticals LLC
Profiel
Erik De Clercq has been a Director of FermaVir Pharmaceuticals, Inc. since August 16, 2005 and FermaVir Research, Inc. since March, 2005.
He has been working with Rega Institute in Leuven since 1977.
Dr. De Clercq is a Professor of the Medical School at Leuven University, Leuven, Belgium.
He is Chairman and a Director of the Rega Institute and the Rega Foundation and Chairman of the Department of Microbiology and Immunology at Leuven University.
Actieve functies van Erik de Clercq
| Bedrijven | Functie | Begin |
|---|---|---|
FermaVir Pharmaceuticals LLC
 FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Directeur/Bestuurslid | 16-08-2005 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | Health Technology |
